Cui, Yuxin, Li, Zhilei, Cao, Junxia, Lane, Jane ORCID: https://orcid.org/0000-0002-1926-4909, Birkin, Emily, Dong, Xuefei and Jiang, Wen G. ORCID: https://orcid.org/0000-0002-3283-1111 2021. The G4 resolvase DHX36 possesses a prognosis significance and exerts tumour suppressing function through multiple causal regulations in non-small cell lung cancer. Frontiers in Oncology 11 , 655757. 10.3389/fonc.2021.655757 |
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (4MB) | Preview |
Abstract
Lung cancer is one of the most prevalent cancers in both men and women worldwide. The nucleic acid G4 structures have been implicated in the transcriptional programmes of cancer-related genes in some cancers such as lung cancer. However, the role of the dominant G4 resolvase DHX36 in the progression of lung cancer remains unknown. In this study, by bioinformatic analysis of public datasets (TCGA and GEO), we find DHX36 is an independent prognosis indicator in non-small-cell lung carcinoma (NSCLC) with subtype dependence. The stable lentiviral knockdown of the DHX36 results in accelerated migration and aggregation of the S-phase subpopulation in lung cancer cells. The reduction of DHX36 level de-sensitises the proliferation response of lung cancer cells to chemotherapeutic drugs such as paclitaxel with cell dependence. The knockdown of this helicase leads to promoted tumour growth, demonstrated by a 3D fluorescence spheroid lung cancer model, and the stimulation of cell colony formation as shown by single-cell cultivation. High throughput proteomic array indicates that DHX36 functions in lung cancer cells through regulating multiple signalling pathways including activation of protein activity, protein autophosphorylation, Fc-receptor signalling pathway, response to peptide hormone and stress-activated protein kinase signalling cascade. A causal transcriptomic analysis suggests that DHX36 is significantly associated with mRNA surveillance, RNA degradation, DNA replication and Myc targets. Therefore, we unveil that DHX36 presents clinical significance and plays a role in tumour suppression in lung cancer, and propose a potentially new concept for an anti-cancer therapy based on helicase-specific targeting.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Publisher: | Frontiers Media |
ISSN: | 2234-943X |
Funders: | This work was financially supported by grants from Cancer Research Wales, Life Sciences Research Network Wales and the Realcan Fellowship |
Date of First Compliant Deposit: | 12 April 2021 |
Date of Acceptance: | 6 April 2021 |
Last Modified: | 02 May 2023 17:28 |
URI: | https://orca.cardiff.ac.uk/id/eprint/140426 |
Citation Data
Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |